<DOC>
	<DOCNO>NCT01881828</DOCNO>
	<brief_summary>The objective propose research evaluate efficacy safety use metformin addition standard insulin therapy overweight obese child adolescent , age 12- &lt; 20 year , type 1 diabetes least 1 year . Secondary objective assess effect metformin C-peptide level , measure much insulin still produce beta cell pancreas , vascular dysfunction . In addition , ancillary study plan ass metformin improve tissue-specific insulin resistance type 1 diabetes use hyperinsulinemic euglycemic clamp .</brief_summary>
	<brief_title>Metformin Therapy Overweight Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Clinical diagnosis presume autoimmune type 1 diabetes ( T1D ) indicate age diagnosis &lt; 10 year document positive diabetesrelated autoantibody . . Note : For randomization , presence least one diabetesrelated autoantibody [ Insulin autoantibody ( IAA ) diagnosis prior initiation insulin , Islet cell antibody ( ICA ) , AntiGAD ( GAD65 ) , AntiIA2 ( IA2 ) , Zinc Transporter 8 ( ZnT8 ) ] must document either medical record new laboratory measurement ( IAA ICA measure central lab ) send central lab participant ≥10 year old diagnosis . 2 . Age : 12 &lt; 20 year . 3 . Duration type 1 diabetes : ≥1 year . 4 . Current insulin regimen involve either use insulin pump multiple daily injection insulin ( least 3 shot per day ) last three month , plan switch modality insulin administration next 6 month ( e.g. , injection user switch pump , pump user switch injection ) . 5 . Hemoglobin A1c : 7.5 % &lt; 10.0 % point care measurement local lab day screen visit within 1 month prior . 6 . BMI : ≥85th percentile adjust age sex . 7 . Total daily dose insulin : ≥0.8 unit per kg per day . 8 . Average ≥3 SelfMonitoring Blood Glucose ( SMBG ) test per day prior initiate study download studyprovided blood glucose meter follow screen visit . 9 . Available least 6 month followup , home phone ( access phone ) , willing contact clinical site staff . 10 . Expected comply protocol investigator 's judgment . 1 . Use noninsulin medication blood glucose control within prior 6 month plan use within next 6 month ( study drug ) . 2 . Use medication weight reduction ( : Belviq ( lorcaserin ) , Qsymia ( Phentermine + topiramate ) , Orlistat ( xenical ) ) within prior 6 month plan use within next 6 month . 3 . Use medication stimulant , psychotropic agent oral/inhaled glucocorticoid could affect weight gain glycemic control T1D planning use within next 6 month . 4 . Any condition judgment investigator adversely affect completion protocol . 5 . Females : pregnant , lactating , intend become pregnant within next 34 week A negative urine pregnancy test require female An effective contraceptive method abstinence require female experience menarche Requirements regard pregnancy test prior enrollment monitoring pregnancy course study may define individual Institutional Review Board ( IRB ) 6 . Clinical diagnosis celiac disease poor control define recent tissue transglutaminase ( tTG ) abnormal range . 7 . History ≥1 diabetic ketoacidosis event past 3 month . 8 . History ≥1 severe hypoglycemic event ( cognitive impairment require assistance treat ) past 3 month . 9 . History anemia vitamin B12 deficiency past 2 year . 10 . Participation intervention study past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>